Home Tags GSK plc

Tag: GSK plc

Moderna shares plunge on plans to cut $1.1 billion in costs, launch 10 new products by 2027
Business

Moderna shares plunge on plans to cut $1.1 billion in costs, launch 10 new products by 2027

(imran) News@GWM -
0
Moderna stock falls 20% as it slashes guidance on low EU sales, tough U.S. vaccine market
Health

Moderna stock falls 20% as it slashes guidance on low EU sales, tough U.S. vaccine market

(imran) News@GWM -
0
Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
Health

Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline

(imran) News@GWM -
0
FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections
Health

FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections

(imran) News@GWM -
0
FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach
Business

FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach

(imran) News@GWM -
0
Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits
Health

Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits

(imran) News@GWM -
0
FDA approves Moderna’s RSV vaccine for seniors, the company’s second-ever product
Health

FDA approves Moderna’s RSV vaccine for seniors, the company’s second-ever product

(imran) News@GWM -
0
Moderna says FDA delayed RSV vaccine approval to end of May
Health

Moderna says FDA delayed RSV vaccine approval to end of May

(imran) News@GWM -
0
FTC challenges ‘junk’ patents held by 10 drugmakers, including for Novo Nordisk’s Ozempic
Health

FTC challenges ‘junk’ patents held by 10 drugmakers, including for Novo Nordisk’s Ozempic

(imran) News@GWM -
0
Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
Health

Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use

(imran) News@GWM -
0
12Page 1 of 2
© Newspaper WordPress Theme by TagDiv